These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10789059)

  • 1. Some physicochemical properties of mefenamic acid.
    Adam A; Schrimpl L; Schmidt PC
    Drug Dev Ind Pharm; 2000 May; 26(5):477-87. PubMed ID: 10789059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of melt sonocrystallization on pharmacotechnical properties of paracetamol, indomethacin and mefenamic acid characterized by dynamic laser scattering and its impact on solubility.
    Kumar B; Sharma V; Pathak K
    Drug Dev Ind Pharm; 2013 May; 39(5):687-95. PubMed ID: 22630048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance.
    Antonio M; Maggio RM
    J Pharm Biomed Anal; 2018 Feb; 149():603-611. PubMed ID: 29202439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of the thermal, spectroscopic and drug dissolution properties of mefenamic acid and polyoxyethylene-polyoxypropylene solid dispersions.
    Andrews GP; Zhai H; Tipping S; Jones DS
    J Pharm Sci; 2009 Dec; 98(12):4545-56. PubMed ID: 19399827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of crystal habits on the surface energy and cohesion of crystalline powders.
    Shah UV; Olusanmi D; Narang AS; Hussain MA; Gamble JF; Tobyn MJ; Heng JY
    Int J Pharm; 2014 Sep; 472(1-2):140-7. PubMed ID: 24928138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid-state characterization of mefenamic acid.
    Panchagnula R; Sundaramurthy P; Pillai O; Agrawal S; Raj YA
    J Pharm Sci; 2004 Apr; 93(4):1019-29. PubMed ID: 14999737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salts of Mefenamic Acid With Amines: Structure, Thermal Stability, Desolvation, and Solubility.
    Bouanga Boudiombo JS; Jacobs A
    J Pharm Sci; 2018 Dec; 107(12):3014-3021. PubMed ID: 30118731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoupling the contribution of surface energy and surface area on the cohesion of pharmaceutical powders.
    Shah UV; Olusanmi D; Narang AS; Hussain MA; Tobyn MJ; Hinder SJ; Heng JY
    Pharm Res; 2015 Jan; 32(1):248-59. PubMed ID: 25037862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of loading volume of mefenamic acid on granules and tablet characteristics using a compaction simulator.
    Kimura G; Betz G; Leuenberger H
    Pharm Dev Technol; 2007; 12(6):627-35. PubMed ID: 18161636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of drug load on dissolution behavior of tablets containing a poorly water-soluble drug: estimation of the percolation threshold.
    Wenzel T; Stillhart C; Kleinebudde P; Szepes A
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1265-1275. PubMed ID: 28398095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and evaluation of fast-release mephenamic acid microspheres.
    Etman M; Farid R; Nada A; Ebian A
    J Microencapsul; 2010; 27(7):640-56. PubMed ID: 20681746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryomilling-induced solid dispersion of poor glass forming/poorly water-soluble mefenamic acid with polyvinylpyrrolidone K12.
    Kang N; Lee J; Choi JN; Mao C; Lee EH
    Drug Dev Ind Pharm; 2015 Jun; 41(6):978-88. PubMed ID: 24849785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing capping and cracking of mefenamic acid tablets.
    Adam A; Schrimpl L; Schmidt PC
    Drug Dev Ind Pharm; 2000 May; 26(5):489-97. PubMed ID: 10789060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of crystal morphology-dependent adhesion behavior of mefenamic acid during tableting.
    Waknis V; Chu E; Schlam R; Sidorenko A; Badawy S; Yin S; Narang AS
    Pharm Res; 2014 Jan; 31(1):160-72. PubMed ID: 23943544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-inflammatory drug (mefenamic acid) incorporated in biodegradable alginate beads: development and optimization of the process using factorial design.
    Sevgi F; Kaynarsoy B; Ertan G
    Pharm Dev Technol; 2008; 13(1):5-13. PubMed ID: 18300095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicomponent Crystal of Mefenamic Acid and N-Methyl-d-Glucamine: Crystal Structures and Dissolution Study.
    Zaini E; Fitriani L; Sari RY; Rosaini H; Horikawa A; Uekusa H
    J Pharm Sci; 2019 Jul; 108(7):2341-2348. PubMed ID: 30779887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of dissolution and absorption of mefenamic acid by egg albumin.
    Imai T; Nohdomi K; Acartürk F; Otagiri M
    J Pharm Sci; 1991 May; 80(5):484-7. PubMed ID: 1880730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naproxen particle design using porous starch.
    Nagata K; Okamoto H; Danjo K
    Drug Dev Ind Pharm; 2001 Apr; 27(4):287-96. PubMed ID: 11411896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites.
    Pomázi A; Ambrus R; Sipos P; Szabó-Révész P
    J Pharm Biomed Anal; 2011 Sep; 56(2):183-90. PubMed ID: 21652159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and investigation of mefenamic acid - polyethylene glycol - sucrose ester solid dispersions.
    Fülöp I; Gyéresi Á; Kiss L; Deli MA; Croitoru MD; Szabó-Révész P; Aigner Z
    Acta Pharm; 2015 Dec; 65(4):453-62. PubMed ID: 26677901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.